Arcellx (ACLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Arcellx (NASDAQ:ACLX – Free Report) had its price objective boosted by Bank of America from $84.00 to $100.00 in a research ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A ...

Truist raised the firm’s price target on Arcellx (ACLX) to $136 from $87 and keeps a Buy rating on the shares after its Q3 results. The ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on ACLX stock, giving a Buy rating on November 8. Daina ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

Arcellx (ACLX) announced an update for its Phase 3 iMMagine-3 study and plans to present Phase 1 and 2 data for anito-cel in ...

Arcellx (NASDAQ:ACLX – Free Report) had its price target raised by Piper Sandler from $91.00 to $115.00 in a report issued on ...

During the last three months, 7 analysts shared their evaluations of Arcellx ACLX +4.99% Get Free Report , revealing diverse ...

Arcellx Inc, a biotechnology firm focused on cell therapy innovations, has announced impressive results from its studies on ...

It’s an exciting time at Arcellx! We are preparing for the commercial launch of anito-cel as there remains an unmet need for a therapy that physicians can use across a broad patient population.” ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ...